The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Gilteritinib plus venetoclax for R/R FLT3-mutated AML
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX discusses the data from an ongoing Phase Ib trial (NCT03625505) of gilteritinib (gilt) and venetoclax, a BCL-2 inhibitor, as combination therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). Gilt is a FLT3 inhibitor which demonstrates superior efficacy to salvage chemotherapy in the FLT3-mutated population. However, relapses remain a common problem, making combination therapies with the potential to prevent resistance of great interest. Given preclinical evidence of synthetic lethality resulting from combining FLT3 inhibitors and apoptotic agents, patients were treated with the established Phase II dose of gilt and venetoclax to assess composite complete remission (CR) rates. The results show an increase in antileukemic activity using the combination, compared to gilt alone. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
